All Episodes
BioCentury This Week — 383 episodes
Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first
Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline
Ep. 371 - Moving faster at the academia-industry interface
Ep. 370 - Calmer waters for FDA; Servier, Lilly deals
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Ep. 368 - ASCO Preview, China Policy, ADC Linkers
Ep. 367 - FDA, obesity targets and the rise of DACs
Ep. 366 - Europe's need for speed: Bio€quity takeaways
Ep. 365 - Thin ice for Makary, redosing AAVs
Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
Ep. 362 - AACR: Data and de-risking
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
Ep. 359 - 2Q markets preview, tariffs and biotech takeouts
Ep. 358 - Europe's biotech challenge
Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
Ep. 354 - East-West Summit Takeaways
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos
Ep. 346 - 2026 Public Markets Preview
Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN
Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation
Ep. 343 - JPM Deals, Policy Outlook, Approval Trends
Ep. 342 - 2026 Biotech Kickoff
Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI
Ep. 340 - Obesity Data, Kymera & FDA Survey Results
Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult
Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, Cell, Gene Therapy Funding
Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc
Ep. 336 - Cautious Optimism and M&A Momentum
Ep. 335 - Neurology's Coming Inflection Point
Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi
Ep. 333 - Is This Korea’s Biotech Moment?
Ep. 332 - Obesity in Focus. Plus: What’s Next for FDA
Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster
Ep. 330 - China's Innovation Moment
Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors
Ep. 328 - Brain Shuttles, GSK Q&A and FDA Vouchers
Ep. 327 - Where Gene & Cell Therapy Go Next With Evotec's Bernd Mühlenweg
Ep. 326 - Market Outlook, Biosecure Returns, Biotech M&A
Ep. 325 - Pfizer MFN Deal, New Trial Paradigm & Billion $ Fund
Ep. 324 - Genmab, GSK and Drug Pricing
Ep. 323 - Agentic AI: From New Targets to the Clinic
Ep. 322 - Takeaways from BioCentury Grand Rounds Europe
Ep. 321 - Pfizer’s Obesity Play & U.K. in Focus
Ep. 320 - U.K. Biotech, U.S.-China, Insmed
Ep. 319 - David Baltimore’s Legacy, Atlas Fund, MASH Pipeline and more
Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines
Ep. 317 - Biotech IPOs, FDA-Stealth & Patent Threat
Ep. 316 - Trends in Pharma Deals
Ep. 315 - China Speed: Data, Deals, First in Class
Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecure
Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer
Ep. 312 - Biotech Progress Report
Ep. 311 - The Asia Deals Landscape, U.K. Biotech & More
Ep. 310 - Sarepta & What's Next for Gene Therapy. Plus: Leading FDA's CDER
Ep. 309 - 3Q Markets Preview; Quantum Computing; Makary’s First 100 Days
Ep. 308 - Grand Rounds - Europe Preview
Ep. 307 - How Cancer Regulation is — and isn’t — Changing at FDA
Ep. 306 - Treg Inflection Point; Biotech's Next Big Story; Tax Bill Consequences
Ep. 305 - FDA's Future; In Vivo CAR T Plays; Psychedelics; CDK2
Ep. 304 - Syncona Reshapes Fund; Lilly's $1B Verve Bet; FDA's 2-Track Future
Ep. 303 - Gene Therapy Safety, Amylin in Obesity & FDA's Future
Ep. 302 - Takeaways from BioCentury Grand Rounds Chicago
Ep. 301 - ASCO’s First-in-Human Trials, Crossover Investors & FDA's Rare Disease Plans
Ep. 300 - Biotech’s $13B Deal Day, ASCO's Hot Targets, Drug Pricing Threat
Ep. 299 - ASCO, EpCAM, Rocket & HK IPOs
Ep. 298 - Takeaways from the 25th Bio€quity Europe
Ep. 297 - European Biotech's Moment? Plus: Biomarin, Boston Deals & Novo Nordisk CEO
Ep. 296 - Trends in Obesity, Vinay Prasad at FDA, Ovarian Cancer Insights
Ep. 295 - Bio€quity Europe 2025 Preview
Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing
Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs
Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview
Ep. 291 - Grand Rounds - U.S. Preview
Ep. 290 - Biotech Survey Sees Tough Days Ahead. Plus: FDA, China Speed
Ep. 289 - Replacing Animal Models. Plus: RFK Jr. & FDA
Ep. 288 - FDA and Tariffs Turmoil, and AACR Preview
Ep. 287 - The Bear is Back: Marks’ Ouster, Tariffs and a Tumbling XBI
Ep. 286 - Sofinnova’s Pan-European Accelerator, China Biotechs, Trump Tariffs
Ep. 285 - BIO's Trump 2.0 Plan. Plus: Autoimmune CAR Ts & Telix's Radiopharma Play
Ep. 284 - Takeaways from the East-West Summit
Ep. 283 - Makary’s FDA Agenda, Amylin in Obesity and Life After DEI
Ep. 282 - CRISPR Lessons: Plus, AbbVie Enters Obesity
Ep. 281 - Roche Reboot and 5 Things on Trump 2.0
Ep. 280 - China Competition. Plus: FDA Firings and Biotech IPOs
Ep. 279 - East-West Summit Preview
Ep. 278 - Trump 2.0’s Impact on FDA, NIH. Plus: Precision Medicine
Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug
Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler
Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH
Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI
Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds
Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma
Ep. 271 - Biotech in the New Year. Plus: Beyond Biosecure
Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data
Bonus Content - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
Ep. 269 - Trends in VC Funds, Obesity Start-ups and More
Ep. 268 - Biosecure Setback & Novartis' $1B PTC Deal
Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts
Ep. 266 - Jefferies Recap, FDA Commissioner & Biosecure Update
Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals
Ep. 264 - Prepping for Trump & Alzheimer's Ethics
Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser
Ep. 262 - EGFR Case Study, FDA & Politics
Ep. 261 - China Summit: Reinventing Your China Strategy
Ep. 260 - VC Funds, New Chapter for MS, Wave's Data
Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA
Ep. 258 - Breaking the Bear: 4Q Public Markets Preview
Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update
Ep. 256 - ESMO Recap: Keeping TIGIT Alive, Rybrevant & Immunotherapy Anniversary
Ep. 255 - Pediatric PRVs, Biosecure & Novo's Obesity Miss
Ep. 254 - Takeaways from Grand Rounds 2024
Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech
Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset
Ep. 251 - Eyes on the target: a Back to School Overview
Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery
Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update
Ep. 248 - Grand Rounds Preview: Eyes on the Target
Ep. 247 - Drug Pricing, Psychedelic Setback & Back to School
Ep. 246 - Wilson’s Vision for Gene Therapy. Plus: Korea Biotech & Grand Rounds
Ep. 245 - Biotech-Academia Deals, Leqembi's Latest, Wilson Moves On
Ep. 244 - Leqembi's Thumbs-Down in Europe. Plus: Perioperative Cancer, Pediatric Review Vouchers
Ep. 243 - Radiopharma Alpha Emitters, AZ’s Galbraith and LNPs
Ep. 242 - 3Q Markets Preview, Washington Update, Lisa Burns
Ep. 241 - U.K. Biopharma on the Move. Plus: IRA, Biosecure
Ep. 240 - Chevron Ruling's Impact. Plus: Tumor Targets, Lurie Winner
Ep. 239 - Rare Disease Spotlight: MPS & DMD
Ep. 238 - Biosecure Act: The Impact & What's Ahead
Ep. 237- Pandemic Prep Problems, Reverse Mergers, Alzheimer’s & SCOTUS
Ep. 236 - BIO Wrap: Biosecure, Japan & Nxera, Radiopharma
Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations
Ep. 234 - Biotech M&A, Biosecure Expands & ASCO Update
Ep. 233 - ASCO Preview, Rare Diseases & Biogen M&A
Ep. 232 - Shake up at BIO. Plus: ASGCT highlights, new IPF & obesity data
Bonus Content - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more
Ep. 231 - Biosecure Revised. Plus: Venture Rounds, Deals of Note
Bonus Content - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise
Ep. 230 - Bio€quity Europe 2024 Preview
Ep. 229 - ASGCT Preview, Accelerated Approval Plus: The Latest in Biosecure
Ep. 228 - Energizing Gene Therapy. Plus: AI Newco, Ono-Deciphera
Ep. 227 - Defending Accelerated Approval. Plus: Endpoint Innovation & AIM Amiss
Ep. 226 - Vertex’s Alpine Buy, Goldman’s Venture & IRA Tea Leaves
Ep. 225 - 2Q Markets Preview & AACR Takeaways
Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS
Ep. 223 - Biosecure, Bruce Booth & Ultrarare Drugs
Ep. 222 - Crowley’s Vision for BIO, Plus: MASH & CAR Ts
Ep. 221 - China Biocontroversy, Plus: Diversity Matters
Ep. 220 - Biotech’s Financing Flurry & Distillery Spotlight
Ep. 219 - East-West Summit Preview
Ep. 218 - Bob Nelsen Insights, TL1A, Rare Diseases
Ep. 217 - Safer CAR Ts & World’s First TIL Therapy
Ep. 216 - Anti-China Biotech Policy: Biosecure & Beyond
Ep. 215 - ADCs, Psychedelics & IPOs
Ep. 214 - BMS’s Patent Cliff, Congress Targets China Biotech
Ep. 213 - Biotech IPOs & IL-18 Momentum
Ep. 212 - 2024 Buyside View & Arnold Ventures' Impact
Ep. 211 - 2024 Markets Preview, Woodcock's Legacy
Ep. 210 - J.P. Morgan Healthcare Conference Wrap
Ep. 209 - Biotech M&A, Innovation, Public Policy in 2024
Ep. 208 - XBI Rally, ASH Highlights & '24 Picks
Ep. 207 - Sickle Cell, AbbVie Deals, BIO CEO, March-in
Ep. 206 - Roche, AbbVie Deals; Plus: FDA & CAR T
Ep. 205 - Radiotherapy Deep Dive; Plus: Congress, BioNTech
Ep. 204 - First CRISPR Approval & IRA’s Lost Orphans
Ep. 203 - POC for Verve? Plus: IRA & East-West Deals
Ep. 202 - A DMD Decision & Endpoint Innovation
Ep. 201 - ESMO, NIH & IRA
Ep. 200 - Merck-Daiichi, Roche-Roivant, Base Editors
Ep. 199 - China Summit Preview
Ep. 198 - Novartis Finds Focus & EU Pharma Law
Ep. 197 - Mirati Takeout & 4Q23 Financial Markets Preview
Ep. 196 - CAR T's Next Act & Hudson's Vision for Sanofi
Ep. 195 - East-West Summit Preview
Ep. 194 - IPO Outlook & IRA Lawsuits
Ep. 193 - East-West CAR T Deals, Plus: Amgen-FTC
Ep. 192 - Tier-jumpers: a Back to School Overview
Ep. 191 - Circular RNA, Psychedelics, & Upcoming BioCentury Summits
Ep. 190 - Obesity Mechanisms, Noubar Takeaways, Scleroderma Platform Trial
Ep. 189 - Biogen-Sage Setback, Biotech IPOs, Sanofi Digital
Ep. 188 – Pharma deals; Plus: Genentech, Leerink Conversations
Ep. 187 - Alnylam-Roche; Plus: Insights on the IRA, FTC
Ep. 186 - 3Q Markets Preview, Donanemab & Lilly-Versanis
Ep. 185 - Leqembi's Launch, Biotech IPOs, Sarepta Approval
Ep. 184 - Califf's FDA reforms & Polaris' Schulman
Ep. 183 - EMA's Cooke, What's Next for IPSCs, & Leerink is Back
Ep. 182 - Merck’s IRA suit, Leqembi and MCEDs at ASCO
Ep. 181 - Highlights from ASCO
Ep. 180 - ASCO, Neuropsych & the IRA
Ep. 179 - DMD Gene Therapies, CBER & NIH
Ep. 178 - Live from Bio€quity, Part 2
Ep. 177 - Live from Bio€quity, Part 1
Ep. 176 - Bio€quity Europe 2023 Preview: Crafting a European Playbook for Success
Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints
Ep. 174 - EC Pharma Law, ALS Biomarker, Astellas' Iveric Deal
Ep. 173 - EU VC Funds, Abortion Drug Ruling, IRA Insights
Ep. 172 - AACR Insights
Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology
Ep. 170 - Abortion Ruling & FDA; New VC Funds; IRA
Ep. 169 - FTC & Illumina, Plus: PCSK9s at SCOTUS
Ep. 168 - VCs' Take on SVB & New ALS Endpoint
Ep. 167 - The IRA, T Cell Therapies & The Distillery
Ep. 166 - SVB Shakeout: Next Steps for Biotech
Ep. 165 - SVB Fallout, Plus: Pfizer-Seagen
Ep. 164 - Viehbacher’s Vision, NK Cells & Bat Biotech
Ep. 163 - EU Pharma Law Overhaul, Abortion Drug Ruling, Dunn's Departure
Ep. 162 - New CMS Payment Models, China Markets Outlook, & Zhang's Latest Start-Up
Ep. 161 - New Cancer Paradigms, Distilling Innovations, & IPOs
Ep. 160 - Dose Optimization, Clinical Trials Diversity and QALYs
Ep. 159 - BIO's Priorities, ESG & Venture Trends
Ep. 158 - CAR T Manufacturing & Orphan Drugs
Ep. 157 - 2023 Markets Outlook & Buyside Picks
Ep. 156 - JPM Highlights & Alzheimer's Takeaways
Ep. 155 - U.K. Biotech, Aduhelm, 2022 Approval Trends
Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery
Ep. 153 - The Inflation Reduction Act
Ep. 152 - Amgen's Horizon Takeout. Plus: ASH, SERDs
Ep. 151 - Alzheimer's Takeaways, U.K. Biotech, Charles Forum
Ep. 150 - Model Term Sheets, Pragmatic Trials & Gene Therapy Prices
Ep. 149 - Takeaways from the East-West Summit
Ep. 148 - East-West Summit Highlights Part 2
Ep. 147 - East-West Summit Highlights Part 1
Ep. 146 - What's Next in Washington, Plus: SITC & the Distillery
Ep. 145 - What's Next for BIO, Plus: Pfizer, GSK
Ep. 144 - Alnylam's IRA Pause, Plus Argenx & Accumulus
Ep. 143 - East-West Summit Preview
Ep. 142 - Lundbeck, Biogen, Biden & Biomanufacturing, Nora Volkow
Ep. 141 - Neoantigen Vaccines, Drug Pricing, U.S.-China & U.K. Turmoil
Ep. 140 - Turbulence at BIO, Plus 4Q Preview & the Distillery
Ep. 139 - Wins in Neurodegeneration, U.S.-China & Life Science Cares
Ep. 138 - FDA User Fee Endgame, East-West Summit & Biogen
Ep. 137 - Intellia's Data, IRA's Orphan Impact, CFIUS Order
Ep. 136 - IRA, KRAS & ESMO
Ep 135 Pt. 5 - A Portrait of Biopharma's New Leaders
Ep 135 Pt. 4 - Filling Biopharma's Talent Pipeline
Ep 135 Pt. 3 - Rising Leaders & the VC View on Talent
Ep 135 Pt. 2 - CEOs in the Spotlight. Plus: Women Leaders, DEI
Ep 135 Pt. 1 - Back to School 2022 Overview
Ep. 134 - Preclinical Deal Making, Bluebird's Approval & Epigenome Editing
Ep. 133 - Financing Thaw? Plus: Protein Design & China Audits
Ep. 132 - M&A & Data: recipe for a rebound?
Ep. 131 - Seagen, New Modalities & Structure
Ep. 130 - Steady as a Roche. Plus: Washington Turbulence
Ep. 129 - Burr Bill, Novartis Makeover, ALS Update
Ep. 128 - Financial Markets Forecast, AAV Toxicity & Drug Pricing
Ep. 127 - TeneoTwo, Lightspeed, Arch & The Distillery
Ep. 126 - Growing Galapagos, Plus Abortion & Biopharma
Ep. 125 - Next Steps for ARPA-H
Ep. 124 - CRISPR's High Bar, Private Equity Inroads and the Distillery
Ep. 123 - Fixing FDA's Broken Advisory Panels
Ep. 122 - ASCO's Advances & Fixes for FDA's AdComms
Ep. 121 - ASCO, CRISPR IP & CStone
Ep. 120 - Next-gen NK cells, Plus Woodcock & BMS’s Russian Withdrawal
Ep. 119 - Bio€quity Recap, Part 2
Ep. 118 - Bio€quity Recap, Part 1
Ep. 117 - Sofinnova Partners’ Growth Deal, Plus Distillery on Tap
Ep. 116 - The Road to Bio€quity 2022: Navigating Through Talent & Capital Headwinds
Ep. 115 - FDA Reform on Deck, Plus Translation at Howard
Ep. 114 - Hutchmed Setback, FDA in Focus, HilleVax's IPO
Ep. 113 - Nkarta’s Breakthrough, Hatch’s Legacy & Shanghai’s Lockdown
Ep. 112 - Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts
Ep. 111 - Seeking Green Shoots Amid Biotech’s Gloom
Ep. 110 - Aduhelm’s Lessons, Plus Distillery Discoveries, Rare Disease Innovation
Ep. 109 - What's Next for Novartis? Plus: AACR, Merck KGaA
Ep. 108 - AACR Preview for CAR Ts in Solid Tumors; Plus FDA Weighs in on Data for ALS Ad Com
Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up
Ep. 106 - China's C-suite Hears FDA, Plus AACR, ARPA-H
Ep. 105 - War Pulls Biotech to Ukraine, Out of Russia
Ep. 104 - Biotech Shows Support for Ukraine, Plus Latest Intellia Data
Ep. 103 - Califf’s Priorities for Second Stint as FDA Commissioner
Ep. 102 - What FDA's Tyvyt Precedent Means for China; plus Translational Trendspotting
Ep. 101 - Of Biotech Bears, Pazdur & PDUFA
Ep. 100 - Capital markets check in; plus Belgium’s prodigal son returns
Ep. 99 - Introducing The BioCentury Show, Plus Califf, COVID and GSK
Ep. 98 - Bargain Hunting in a Rocky Market, plus Advantage, CMS
Ep. 97 - Buysiders' Picks, plus JPM22 roundup
Ep. 96 - Aduhelm, Pazdur, Pharma Digital & '21 Wrap
Ep. 95 - ASH's New Targets, Avistone & Washington Update
Ep. 94 - Woodcock's To-Do List, Maraganore's Takeaways & the Distillery
Ep. 93 - Omicron's Open Questions, Plus the Business Case for Ultra-rare Diseases
Ep. 92 - Biogen’s R&D decision, previewing TIGIT & China Summit highlights
Ep. 91 - China Summit Highlights: Day 2
Ep. 90 - China Summit Highlights: Day 1
Ep. 89 - Califf's Passions, RWE in China & LSP Rising
Ep. 88 - China Summit Preview: The Bridge to Innovation
Ep. 87 - Digesting Drug Pricing, Plus Access in ALS
Ep. 86 - Woodcock's Legacy, Plus Frazier, Bain & the Distillery
Ep. 85 - What's Next for CRISPR & Gene Therapy, Plus China Summit Preview
Ep. 84 - Why Gene Therapy's Bad Year Is a Speed Bump, Not a Dead End
Ep. 83 - Assessing Biogen’s ALS Miss, Plus Califf on Deck
Ep. 82 - 4Q Markets Preview, Plus the Future of NIH
Ep. 81 - Merck & the State of M&A, Plus Novartis CEO's Call to Action
Ep. 80 - Hong Kong Rising, Plus Varmus' POV & Biden's FDA Choice
Ep. 79 - ESMO, Jeito & the Latest from Washington
Ep. 78 - Remembering Fred Frank, Lisa Raines, Plus CRISPR, Washington Updates
Ep. 77 - Back to School Spotlight & Pressures on FDA
Ep 76 Pt. 4 - Modifying Access for Accelerated Approvals
Ep 76 Pt. 3 - Delivering the Evidence for Accelerated Approval
Ep 76 Pt. 2 - Standards of Evidence for Accelerated Approval
Ep 76 Pt. 1 - Accelerated Approval's Big Picture
Ep. 75 - Back to School Preview, plus Pfizer Eats Trillium
Ep. 74 - Vertex's Road Map & Innovation in MS
Ep. 73 - Next Up in COVID with Otello Stampacchia and Umer Raffat
Ep. 72 - Modality Matters: M&A Heats Up, Galbraith Maps AZ's BD
Ep. 71 - Lessons from China’s Market Turmoil, Plus Distillery on Tap
Ep. 70 - Prepping for China’s IP law with Jones Day’s Tony Chen
Ep. 69 - Allaying Aduhelm Concerns, Plus Master Protocols, Arvinas-Pfizer
Ep. 68 - Drug Pricing Pressure, Plus European Deal Trends
Ep. 67 - Aduhelm: a Tangled Plot; Plus, INTREPID Pandemic Planning
Ep. 66 - Biotechs hit 3Q with Coolers Full of Cash; plus Distillery on Tap
Ep. 65 - Optimism for Intellia's CRISPR Breakthrough, Concerns about Aduhelm
Ep. 64 - Amyloid Analysis: Stress Testing FDA's Logic on Surrogate Endpoint
Ep. 63 - Woodcock, Noubar and Genmab’s dealmaking: A BioCentury Podcast
Ep. 62 - Reflecting on the Implications of Aduhelm's Approval: A BioCentury Podcast
Ep. 61 - Dissecting FDA's Aducanumab Decision
Ep. 60 - D-Day for Aducanumab: What's at stake
Ep. 59 - KRAS to the Future; plus ARPA-H & EGFR
Ep. 58 - LAG3 Before You Leap; plus BEE21, G20 Highlights
Ep. 57 - Financing Scandinavia; plus IP Waivers, Long Covid & AAV Pays
Ep. 56 - FDA’s ODAC Bind; plus NK Cell Engagers and Company Creation in Europe
Ep. 55 - German Plays Deliver on Data, plus Accelerated Approval on Trial
Ep. 54 - Patient Groups’ Pandemic Pain; plus Voters’ Rights and Synthetic Lethality
Ep. 53 - Competence & Continuity at CDER; plus BIO 3.0, AACR and 2Q Preview
Ep. 52 - Memories of John Martin, plus AACR's Hot Targets & Bio€quity Europe Preview
Ep. 51 - Abernethy & the Obvious at FDA; Plus CEPI & EpimAb
Ep. 50 - FTC & the Zombie Pharma Dinosaurs; Plus: RIP José Baselga, NCATS & SPACs
Ep. 49 - Vaccine Vexed; Plus Assessing Lilly's Alzheimer's Data & PDUFA Preview
Ep. 48 - New Modality Deep Dive; plus Sharpless Speaks & Five Prime Scores
Ep. 47 - Whither Woodcock; plus Refresh for German Biotech & Modalities to Market
Ep. 46 - Pipeline plays for BMS, Rigel; plus J&J's vaccine panel & access for Africa
Ep. 45 - Start-Up Trends, COVID Variants and J&J's Adcomm
Ep. 44 - Biotech's IPO blizzard, plus GameStop, Porter Report & Vaccine Guidance
Ep. 43 - Europe's Next Act & the Porter Report
Ep. 42 - Warp Speed Reflections, Master Protocols & Biden’s COVID Plan
Ep. 41 - Biden's Science Team; Plus: Early Cancer Detection
Ep. 40 - Investors' Picks & Access to Capital in 2021
Ep. 39 - COVID Accountability, Biden's Bidding & Start-up Season
Ep. 38 - Crucible of COVID, Ahoy 2021 & Cancer Deal Trends
Ep. 37 - 2020's Silver Linings, New Year's Hopes
Ep. 36 - Vaccines march forward & CAR Ts move earlier: a BioCentury podcast
Ep. 35 - ASH Monday, Biden's Picks & Vaccine Conundrums
Ep. 34 - Moderna Moves & Immunocore Breaks Through
Ep. 33 - ASH Preview & Long Shot Drug Pricing Rule
Ep. 32 - Moderna Times & China's Future
Ep. 31 - Pfizer & Biogen: The Good, the bAD and What's Next
Ep. 30 - ICER's Influence and Election Effects
Ep. 29 - SPACs & Vax
Ep. 28 - FDA's Future & China Summit Preview
Ep. 27 - CRISPR advances and mega-IPOs: a BioCentury podcast
Ep. 26 - Treating Trump & BMS's $13B MyoKardia buy
Ep. 25 - Alzheimer Milestones & Vaccine Politics
Ep. 24 - Azar's Memo & Biotech's Deals
Ep. 23 - $21B Deal by Gilead, None by PhRMA
Ep. 22 - Back to School, Behind the Scenes
Ep. 21 - FDA’s Credibility on the Line, plus Biotech’s Venture Wave
Ep. 20 - Politics & Plasma
Ep. 19 - I Want KaNDy, Plus Sputnik V & M&A amid COVID-19
Ep. 18 - BIOEquality, Data Sharing and Deals
Ep. 17 - Warp Speed, Decentralized Trials & SPACs
Ep. 16 - Trump's Ultimatum, RADx & Preclinical IPOs
Ep. 15 - Vaccine Hopes, the Shifting Biopharma Workplace & Blueprint's Dx Deal
Ep. 14 - Investor Sentiment, HCQ Redux and Attacking AMR
Ep. 13 - Nuances of NASH, COVID Vaccines and Real-World Data
Ep. 12 - Remdesivir's Price, RWD’s Moment & A Genomics Breakup
Ep. 11 - Funding U.K. Biotechs, plus Global Vaccine Access
Ep. 10 - EUAs, ACTIV & M&A
Ep. 9 - IPOs, Vaccines & BIO's New Leader
Ep. 8 - Financing Flurry & Purchasing Pools
Ep. 7 - FDA takes on COVID-19, plus ASCO's breakthroughs
Ep. 6 - New Faces for COVID-19’s Next Phase, ASCO’s Hot Topics
Ep. 5 - Master Protocols, EUAs and Rick Bright: BioCentury editors on COVID-19
Ep. 4 - End of the beginning for vaccines and the post-pandemic future
Ep. 3 - Surveying the Landscape for Biopharmas
Ep. 2 - Consorting to beat COVID-19
Ep. 1 - Racing to Create Countermeasures